Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.64 |
| ▸ | ANPEP | P15144 | 5/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2527916 | 1.00 | MMP2 (0.64) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| SCHEMBL2399785 | 1.00 | MMP2 (0.64) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| SCHEMBL10084498 | 1.00 | MMP2 (0.64) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| Hydrochloric Acid SCHEMBL3109852 | 0.99 | MMP2 (0.62) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| Hydrochloric Acid SCHEMBL3109847 | 0.99 | MMP2 (0.62) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| SCHEMBL14117871 | 0.92 | MMP2 (0.52) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| SCHEMBL3102862 | 0.92 | MMP2 (0.52) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| SCHEMBL2521825 | 0.92 | MMP2 (0.52) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| SCHEMBL2400095 | 0.92 | MMP2 (0.52) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| SCHEMBL12166277 | 0.91 | MMP2 (0.62) | MMP2ANPEPSIGMAR1TLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622496-B2 | antiarrhythmia agents; 1-(2-Amino-acetyl)-4-(benzoylamino)-pyrrolidine-2-carboxylic acid; desirable bioavailability properties | ZEALAND PHARMA A/S (DK) | 2009-11-24 | — | — | US | disclosed |
| US-20070149460-A1 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149460-A1 | Modified lysine-mimetic compounds | MYLK2, KCNN2, KCNN1 | MMP2 1902/4885ANPEP 491/4885SIGMAR1 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.